^
Association details:
| Biomarker: | SMARCA4 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | seclidemstat (SP2577) (LSD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
Published date:
05/19/2021
Excerpt:
SALA-003-AC19 (NCT03895684) is a phase 1 trial of single agent SP-2577 in pts with AST...19 pts with AST (10 sarcoma, 2 prostate, 2 ovarian, 2 pancreatic, 1 renal, 1 cervical, 1 breast) were enrolled….Ovarian...Mutation in SMARCA4…Best overall response...SD...
DOI:
10.1200/JCO.2021.39.15_suppl.3073
Trial ID:
